Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 9/20 | 0.79 |
| ▸ | HINT1 | P49773 | 4/20 | 0.60 |
| ▸ | GSK3A | P49840 | 2/20 | 0.58 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5960204 | 0.94 | TYMP (0.69) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL10904155 | 0.94 | TYMP (0.76) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL1904550 | 0.94 | TYMP (0.76) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL18042134 | 0.93 | TYMP (0.68) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL1738400 | 0.93 | TYMP (0.68) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL16702978 | 0.93 | TYMP (0.68) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL21905181 | 0.92 | TYMP (0.67) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL28827051 | 0.91 | TYMP (0.65) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL17223100 | 0.90 | TYMP (0.64) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL8958859 | 0.90 | TYMP (0.64) | TYMPHINT1GSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567009-A2 | ANTISENSE MODULATION OF NOTCH (DROSOPHILA) HOMOLOG 4 EXPRESSION | Isis Pharmaceuticals, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1501854-A2 | ANTISENSE MODULATION OF HMGI-C EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1501941-A1 | ANTISENSE MODULATION OF JAGGED 2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1461419-A2 | ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1461461-A2 | ANTISENSE MODULATION OF CD81 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1461349-A2 | ANTISENSE MODULATION OF MHC CLASS II TRANSACTIVATOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1451363-A2 | ANTISENSE MODULATION OF THYROID HORMONE RECEPTOR INTERACTOR 6 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1436310-A1 | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1417216-A2 | ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION | ISIS Pharmaceuticals, Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1417339-A2 | ANTISENSE MODULATION OF GLIOMA-ASSOCIATED ONCOGENE-2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003000656-A2 | ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR II EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002097108-A2 | ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 5 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002092855-A1 | ANTISENSE MODULATION OF HELICASE-MOI EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002088392-A1 | ANTISENSE MODULATION OF GU PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088162-A1 | ANTISENSE MODULATION OF INTERFERON GAMMA RECEPTOR 1 EXPRESSION | ISIS PHARMACEUTICALS, INC (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088393-A1 | ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002024720-A1 | ANTISENSE MODULATION OF CASPASE 2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002020546-A1 | ANTISENSE MODULATION OF PHOSPHORYLASE KINASE ALPHA 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2001071008-A1 | ANTISENSE INHIBITION OF ADAM10 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2000050440-A1 | ANTISENSE MODULATION OF Smad5 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-31 | — | — | WO | disclosed |